Zydus Lifesciences Limited

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:43:54 2024-05-22 am EDT			5-day change	1st Jan Change
1,081 ^INR	-0.71%		+9.86%	+56.80%

May. 21	Nomura Downgrades Zydus Lifesciences to Neutral From Buy, Adjusts Price Target to INR1,020 From INR988	MT
May. 21	Zydus Lifesciences Records Sharp Rise in Fiscal Q4 Consolidated Profit	MT

Cadila Healthcare : Zydus announces EPICS-IIITM Phase 2(b)/3 adaptive pivotal clinical trial of Saroglitazar Mg in PBC

December 10, 2021 at 04:12 am EST

www.zyduscadila.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation is complete.

Reference ID	IP Address	Date and Time
84eacba4925d0e70d060327c9369023b	3.139.89.176	12/10/2021 09:06 AM UTC

Attachments

Original Link
Original Document
Permalink

Disclaimer

Cadila Healthcare Limited published this content on 10 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 December 2021 09:11:05 UTC.

Latest news about Zydus Lifesciences Limited

Nomura Downgrades Zydus Lifesciences to Neutral From Buy, Adjusts Price Target to INR1,020 From INR988	May. 21	MT
Zydus Lifesciences Records Sharp Rise in Fiscal Q4 Consolidated Profit	May. 21	MT
Jefferies Adjusts Zydus Lifesciences' Price Target to INR1,070 From INR750, Keeps at Hold	May. 20	MT
Transcript : Zydus Lifesciences Limited, Q4 2024 Earnings Call, May 17, 2024	May. 17
Zydus Lifesciences Limited Proposes Final Dividend for the Financial Year Ended on March 31, 2024, Payable on or After August 13, 2024	May. 17	CI
Zydus Lifesciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024	May. 17	CI
Zydus Lifesciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	May. 17	CI
Zydus Lifesciences Gets US FDA Nod to Market Dexamethasone Tablets	May. 12	MT
India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says	May. 10	RE
Zydus Lifesciences Limited Announces Completion of Enrolment for EPICS IIITM Phase 2B/3 Trial Evaluating Saroglitazar Mg in Treatment of Primary Biliary Cholangitis	May. 09	CI
Zydus Lifesciences Gets US FDA Final Nod for Acne Treatment Gel	May. 09	MT
Zydus Lifesciences Limited Receives Final Approval from USFDA for Dapsone Gel, 7.5%	May. 09	CI
Zydus Lifesciences Arm Acquires Eiger BioPharmaceuticals' Progeria Drug	May. 06	MT
Zydus Lifesciences Limited Receives A Demand Order-In-Original for the Financial Year 2018-19	Apr. 29	CI
Zydus Lifesciences Limited Receives A Demand Order-In-Original for the Financial Year 2018-19	Apr. 29	CI
Weak March Quarter Earnings Weigh Down Indian Equities on Friday	Apr. 26	MT
Zydus Lifesciences Gets US FDA's Final Approval for Generic Acne Cream	Apr. 26	MT
Zydus Lifesciences Limited Receives Final Approval from USFDA for Tretinoin Cream USP, 0.1%	Apr. 26	CI
Zydus Lifesciences Limited Receives Demand Order-In-Original for the Financial Year 2018-19	Apr. 25	CI
Zydus Lifesciences Gets 10 Observations from US FDA After Jarod, India Manufacturing Site Inspection	Apr. 24	MT
China Medical System's Anti-Anaemia NDA Accepted in China	Apr. 23	MT
Zydus Lifesciences' Desidustat Tablets Get Nod from China Regulator	Apr. 23	MT
Zydus Lifesciences Limited Announces New Drug Application of Zydus' Innovative Drug Desidustat Tablets by China Medical System Holdings Limited Accepted in China	Apr. 23	CI
Zydus Lifesciences Limited Launches Mirabegron Extended-Release Tablets in the U.S	Apr. 22	CI
Zydus Arm Get UK Drug Regulator's Marketing Approval for Nulibry as MoCD Type A Treatment	Apr. 21	MT

Chart Zydus Lifesciences Limited

Duration

Period

More charts

Company Profile

Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.

Sector

Pharmaceuticals

Calendar

2024-08-06 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Zydus Lifesciences Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1,081 INR

Average target price

989.4 INR

Spread / Average Target

-8.44%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ZYDUS LIFESCIENCES LIMITED	+56.80%	13.15B
OTSUKA HOLDINGS CO., LTD.	+20.08%	22.46B
SANDOZ GROUP AG	+18.55%	15.04B
CIPLA LIMITED	+18.94%	13.98B
ONO PHARMACEUTICAL CO., LTD.	-10.55%	6.89B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.03%	5.71B
RICHTER GEDEON VEGYÉSZETI GYÁR NYILVÁNOSAN MUKÖDO RT.	+6.11%	4.69B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-13.26%	4.33B

Generic Pharmaceuticals

Zydus Lifesciences Limited

Equities

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Cadila Healthcare : Zydus announces EPICS-IIITM Phase 2(b)/3 adaptive pivotal clinical trial of Saroglitazar Mg in PBC

EPS Revisions